Klow Stack (peptidedosingprotocols.com)

approvedv1

tissue repair · approved by martin@gettetonlabs.com

Provider-only template. Not patient-visible. Dosing is source-attributed or a justified provider override. Approval requires safety + monitoring summaries; high/critical safety rules require acknowledgment.

How it works

The KLOW peptide blend combines four peptides: GHK-Cu, KPV, BPC-157, and TB-500, each contributing unique mechanisms to the overall function of the stack. GHK-Cu is a copper-binding peptide that has been linked to skin and connective tissue research, known for its ability to modulate gene expression and promote tissue repair. It has been shown to influence over 4,000 human genes, enhancing collagen and elastin synthesis, which are crucial for skin rejuvenation and structural repair (Pickart and Margolina, International Journal of Molecular Sciences, 2018).

KPV, a tripeptide derived from alpha-melanocyte-stimulating hormone, is included for its anti-inflammatory properties. It has been studied for its ability to inhibit NF-κB activation in intestinal epithelial cells, which is a key pathway in inflammation (Dalmasso et al., Gastroenterology, 2008). While BPC-157 and TB-500 also exhibit anti-inflammatory effects, these are secondary to their primary roles in tissue repair. GHK-Cu's anti-inflammatory effects arise from its broader gene-expression activity, but KPV is unique in its direct targeting of NF-κB-driven cytokine production.

The rationale for combining these peptides is based on their complementary mechanisms. The GLOW stack, which includes GHK-Cu, BPC-157, and TB-500, focuses primarily on structural repair and skin rejuvenation. The addition of KPV in the KLOW stack addresses chronic inflammation, making it suitable for research contexts that involve gut-related models or autoimmune conditions. However, it is important to note that no published study has validated the synergistic effects of these peptides when administered together, and the reasoning for their combination is based on community-derived insights rather than direct evidence. [Source: Peptide Dosing Protocols]

Plain language: The KLOW stack combines four peptides that work together to promote tissue repair and reduce inflammation, with each peptide targeting different biological pathways.

Who should avoid it

Common contraindications for the KLOW peptide blend include:

1. **Active or Recent Cancer**: BPC-157 and TB-500 promote angiogenesis, which could exacerbate cancer growth. 2. **Wilson's Disease or Other Copper Metabolism Disorders**: The GHK-Cu component may lead to complications due to copper accumulation. 3. **Pregnancy or Breastfeeding**: There is no safety data available for any of the components during these conditions. 4. **Athletes Subject to WADA Testing**: BPC-157 and TB-500 are prohibited substances under WADA category S0 — Unapproved Substances. 5. **Individuals on Anticoagulants**: Caution is advised due to the angiogenesis-active components.

It is recommended to stop the protocol and seek medical care if significant symptoms occur, such as pronounced swelling, ongoing dizziness, rapid heart rate, shortness of breath, or marked fatigue. [Source: Peptide Dosing Protocols]

Plain language: People with active cancer, copper metabolism disorders, pregnant or breastfeeding women, athletes in competitive sports, and those on blood thinners should avoid the KLOW stack.

💉 Dosing schedule

All component dosing in one place — verbatim from source or a justified provider override. Not a recommendation. Edit per component below.

Component	Dose	Route	Frequency	Duration	Cycle	Source
GHK-Cuprimary	50 mg	subcutaneous	once daily	4-6 weeks	4-6 weeks on, 2-4 weeks off	Provider override
	Reconstitution: Add 3.0 mL bacteriostatic water to the 80 mg vial.
KPVsupport	10 mg	subcutaneous	once daily	4-6 weeks	4-6 weeks on, 2-4 weeks off	Provider override
	Reconstitution: Add 3.0 mL bacteriostatic water to the 80 mg vial.
BPC-157support	10 mg	subcutaneous	once daily	4-6 weeks	4-6 weeks on, 2-4 weeks off	Provider override
	Reconstitution: Add 3.0 mL bacteriostatic water to the 80 mg vial.
TB-500 / TB4support	10 mg	subcutaneous	once daily	4-6 weeks	4-6 weeks on, 2-4 weeks off	Provider override
	Reconstitution: Add 3.0 mL bacteriostatic water to the 80 mg vial.

Template details

There are no published safety studies on the four-peptide KLOW combination. However, individual compound research and community reports indicate the following:

**Most Frequently Reported Effects**: Mild local effects from subcutaneous injections include redness, mild swelling, or sensitivity at the injection site. A faint blue-green tint at the injection site may occur due to the copper in GHK-Cu. Users have also reported mild fatigue and transient digestive shifts during the first week.

**Less Commonly Reported Effects**: Other effects include headache, light-headedness, vivid dreams (often attributed to BPC-157), and brief appetite changes. None of these effects have been formally measured in controlled studies of the blend.

**Stack-Specific Concerns**: Prolonged use of GHK-Cu raises concerns about copper accumulation, necessitating cycling of 4-6 weeks on and 2-4 weeks off. Both BPC-157 and TB-500 promote angiogenesis, which is a concern for individuals with active or recent malignancy. Additionally, there are unknown interactions due to the lack of pharmacokinetic studies on the combined peptides. Quality control issues may arise as research-use peptides are not held to pharmaceutical-grade standards. [Source: Peptide Dosing Protocols]

Components

GHK-Cuprimary

KPVsupport

BPC-157support

TB-500 / TB4support

Safety rules

Monitoring requirements

Evidence links

Audit history (1)

2026-06-16 02:18:39 · approve_template by martin@gettetonlabs.com — Bulk-approved by provider (peptidedosingprotocols.com stack imports).